A recent meta-analysis of randomized controlled trials (RCTs), including AMPLITUDE-O, examining six GLP-1 receptor agonists (lixisenatide, liraglutide, subcutaneous semaglutide, exenatide, dulaglutide, and efpeglenatide) reported a 21% reduction in a composite kidney outcome (macroalbuminuria, doubling of serum creatinine or 40% eGFR decline, RRT, or death from kidney disease), corresponding to a number needed to treat of 47 [73]
For individuals with a BMI of 30 or higher, semaglutide weight loss programs offer a targeted solution that complements traditional methods like diet and exercise
Delivery Methods Explained: IM, SC, or IV
Medical-grade ingredients Sterile technique Individualized dosing Proper screening protocols All ingredients used in our Glutathione IV Therapy are selected to support antioxidant protection, detoxification, and overall wellness